Paper Details

  1. Home
  2. Paper Details

Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.

Author: BrunetteMary F, CitromeLeslie, CorrellChristoph U, DiPetrilloLauren, GreenAlan I, JiangYing, McDonnellDavid, O'MalleyStephanie S, SilvermanBernard L, SimmonsAdam

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that olanzapine combined with samidorphan was not superior to olanzapine alone in treating alcohol use disorder (AUD) in patients with schizophrenia.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Alcohol use disorder (AUD) is a common comorbidity of schizophrenia. No effective pharmacologic treatment is available for both disorders to date. METHODS: In a phase 2, double-blind study, patients with schizophrenia and AUD experiencing ≥ 10 drinking and ≥ 2 heavy-drinking days in the ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.4088/JCP.19m12786

データ提供：米国国立医学図書館（NLM）

Navigating the Desert of Dual Diagnosis: Olanzapine Plus Samidorphan for Schizophrenia and Alcohol Use Disorder

Schizophrenia and alcohol use disorder (AUD), a challenging combination, often creates a desert of mental health challenges. This study explores the potential of olanzapine plus samidorphan (OLZ/SAM) in treating patients with both disorders. The researchers conducted a phase 2, randomized clinical trial to assess the effectiveness of OLZ/SAM in reducing the risk of disease symptom exacerbation and heavy drinking days.

A Search for a Better Path: OLZ/SAM in Schizophrenia and Alcohol Use Disorder

The study, like a camel searching for a water source in a vast desert, found that OLZ/SAM was not superior to olanzapine alone in reducing the time to the first event of exacerbation of disease symptoms. While the results were not conclusive, the study provides valuable insights into the potential of this combination therapy. Further research is needed to explore the nuances of this complex condition and the potential for more effective treatment options.

Living with Dual Diagnosis: A Multifaceted Approach

Schizophrenia and alcohol use disorder are complex conditions that require a multifaceted approach to treatment. This study underscores the importance of continued research in developing more effective therapies for this challenging population. It also highlights the importance of patient-centered care, tailoring treatment plans to the specific needs of each individual. Like navigating a difficult terrain, a collaborative approach involving healthcare professionals, patients, and their families is essential for achieving successful outcomes.

Dr.Camel's Conclusion

This study provides a glimpse into the potential of olanzapine plus samidorphan (OLZ/SAM) for patients with schizophrenia and alcohol use disorder. While the results were not conclusive, the study highlights the importance of continued research in developing effective treatments for this challenging population. The journey towards better treatment options for dual diagnosis continues, just like a camel seeking the most promising path across the desert of mental health challenges.

Date :
  1. Date Completed 2020-07-21
  2. Date Revised 2020-07-21
Further Info :

Pubmed ID

32160422

DOI: Digital Object Identifier

10.4088/JCP.19m12786

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.